Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 18/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 18/20 | 1.00 |
| ▸ | TLR3 | O15455 | 1/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15070031 | 0.88 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL15070029 | 0.87 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2565162 | 0.82 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL16509889 | 0.82 | HIF1A (0.74) | HIF1AEPAS1TLR3EP300 | |
| SCHEMBL15052348 | 0.77 | EP300 (0.78) | HIF1AEPAS1EP300 | |
| SCHEMBL14571754 | 0.76 | HIF1A (0.66) | HIF1AEPAS1TLR3EP300 | |
| SCHEMBL3193294 | 0.74 | TLR3 (0.59) | HIF1AEPAS1TLR3 | |
| SCHEMBL15052490 | 0.73 | HIF1A (0.76) | HIF1AEPAS1EP300 | |
| SCHEMBL14930310 | 0.72 | HIF1A (0.60) | HIF1AEPAS1EP300 | |
| SCHEMBL14930294 | 0.71 | HIF1A (0.64) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381260-B2 | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381260-B2 | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | EMORY UNIVERSITY (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | EMORY UNIVERSITY (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | HIF1A, HIF1AN, HYOU1 | HIF1A 1/4885EPAS1 28/4885TLR3 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.